Alnylam

Press Releases

Jan 14,2019
Summary ToggleAlnylam Pharmaceuticals Prices Public Offering of Common Stock
PDF Version
Jan 14,2019
Summary ToggleAlnylam Pharmaceuticals Announces Proposed Public Offering of Common Stock
PDF Version
Jan 07,2019
Summary ToggleAlnylam Announces Unaudited Fourth Quarter 2018 Global Revenues for ONPATTRO® (patisiran) and Provides Additional Commercial Updates
PDF Version
Dec 28,2018
Summary ToggleAlnylam to Webcast Presentation at 37th Annual J.P. Morgan Healthcare Conference
PDF Version
Dec 10,2018
Summary ToggleAlnylam Announces Settlement of Litigation with Silence Therapeutics
PDF Version
Dec 06,2018
Summary ToggleAlnylam Provides R&D Updates and Announces 2019 Product and Pipeline Goals at R&D Day
PDF Version
Nov 29,2018
Summary ToggleAlnylam to Webcast R&D Day
PDF Version
Nov 26,2018
Summary ToggleVir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218
PDF Version
Nov 21,2018
Summary ToggleAlnylam to Webcast Presentations at Upcoming Investor Conferences
PDF Version
Nov 09,2018
Summary ToggleAlnylam Presents Updated Phase 1/2 Open-Label Extension (OLE) Results for Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria
PDF Version
Nov 07,2018
Summary ToggleAlnylam Pharmaceuticals Reports Third Quarter 2018 Financial Results and Highlights Recent Period Activity
PDF Version
Nov 06,2018
Summary ToggleAlnylam to Webcast Presentations at Upcoming Investor Conferences
PDF Version
Oct 30,2018
Summary ToggleAlnylam to Webcast Conference Call Discussing Third Quarter 2018 Financial Results
PDF Version
Oct 29,2018
Summary ToggleHochschulmedizin Zurich and Alnylam Host Innovative Medicine Lecture on the Discovery and Clinical Applications of RNA interference (RNAi)
PDF Version
Oct 25,2018
Summary ToggleAlnylam Expands Alnylam Act® Program to Improve Diagnosis of Primary Hyperoxaluria Type 1 (PH1) and Aligns with FDA on Trial Design for ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran
PDF Version
Oct 24,2018
Summary ToggleAlnylam Announces Advocacy for Impact Grants to Inspire Unique Solutions that Address Unmet Needs Affecting the Rare Disease Community
PDF Version
Oct 15,2018
Summary ToggleAlnylam Announces Plan to Initiate Rolling Submission of a New Drug Application and Pursue Full Approval for Givosiran
PDF Version
Oct 10,2018
Summary ToggleAlnylam Appoints Dr. Margaret Hamburg to Board of Directors
PDF Version
Oct 04,2018
Summary ToggleAlnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1
PDF Version
Oct 03,2018
Summary ToggleAlnylam Submits Clinical Trial Authorization (CTA) Application for ALN-AAT02, an Investigational RNAi Therapeutic for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)
PDF Version
Displaying 1 - 20 of 996 results
View all releases

Search

: (Common):

Price:
Change (%):
Volume:
Data as of
Copyright NASDAQ. Minimum 15 minutes delay
Learn More